LUC00072I2 - Niraparib ou un sel pharmaceutiquement acceptable, stéréoisomère ou tautomère de celui-ci, notamment le tosylate ou un hydrate, particulièrement le tosylate monohydraté - Google Patents

Niraparib ou un sel pharmaceutiquement acceptable, stéréoisomère ou tautomère de celui-ci, notamment le tosylate ou un hydrate, particulièrement le tosylate monohydraté Download PDF

Info

Publication number: LUC00072I2
Authority: LU; Luxembourg
Prior art keywords: tosylate; pharmaceutically acceptable; niraparib; tautomer; stereoisomer
Prior art date: 2007-01-10

Application number

LU00072C

Other languages

English (en)

Original Assignee

Msd Italia Srl

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-01-10

Filing date

2018-05-03

Publication date

2018-07-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37809722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LUC00072(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2018-05-03 Application filed by Msd Italia Srl filed Critical Msd Italia Srl

2018-07-04 Publication of LUC00072I2 publication Critical patent/LUC00072I2/fr

Links

150000003839 salts Chemical class 0.000 title abstract 2
PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 title 1
229950011068 niraparib Drugs 0.000 title 1
KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 title 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 title 1
208000024172 Cardiovascular disease Diseases 0.000 abstract 2
206010028980 Neoplasm Diseases 0.000 abstract 2
102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 abstract 2
108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 abstract 2
229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 abstract 2
201000011510 cancer Diseases 0.000 abstract 2
208000001647 Renal Insufficiency Diseases 0.000 abstract 1
206010063837 Reperfusion injury Diseases 0.000 abstract 1
206010057430 Retinal injury Diseases 0.000 abstract 1
206010038997 Retroviral infections Diseases 0.000 abstract 1
208000006011 Stroke Diseases 0.000 abstract 1
241000950638 Symphysodon discus Species 0.000 abstract 1
238000002512 chemotherapy Methods 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
230000002757 inflammatory effect Effects 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
230000000302 ischemic effect Effects 0.000 abstract 1
201000006370 kidney failure Diseases 0.000 abstract 1
230000004770 neurodegeneration Effects 0.000 abstract 1
208000015122 neurodegenerative disease Diseases 0.000 abstract 1
230000009758 senescence Effects 0.000 abstract 1
230000037380 skin damage Effects 0.000 abstract 1
208000019553 vascular disease Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

LU00072C 2007-01-10 2018-05-03 Niraparib ou un sel pharmaceutiquement acceptable, stéréoisomère ou tautomère de celui-ci, notamment le tosylate ou un hydrate, particulièrement le tosylate monohydraté LUC00072I2 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0700432.8A GB0700432D0 (en)	2007-01-10	2007-01-10	Therapeutic compounds

Publications (1)

Publication Number	Publication Date
LUC00072I2 true LUC00072I2 (fr)	2018-07-04

Family

ID=37809722

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU00072C LUC00072I2 (fr)	2007-01-10	2018-05-03	Niraparib ou un sel pharmaceutiquement acceptable, stéréoisomère ou tautomère de celui-ci, notamment le tosylate ou un hydrate, particulièrement le tosylate monohydraté

Country Status (21)

Country	Link
CN (1)	CN101578279B (fr)
AT (1)	ATE502933T1 (fr)
CR (1)	CR10910A (fr)
DE (1)	DE602008005711D1 (fr)
DK (2)	DK2336120T3 (fr)
ES (3)	ES2362214T3 (fr)
GB (1)	GB0700432D0 (fr)
HN (1)	HN2009001260A (fr)
HU (1)	HUE044513T2 (fr)
LT (1)	LT2805945T (fr)
LU (1)	LUC00072I2 (fr)
ME (1)	ME03481B (fr)
MY (1)	MY147789A (fr)
NI (1)	NI200900135A (fr)
NZ (1)	NZ578256A (fr)
PE (1)	PE20081558A1 (fr)
PT (3)	PT2805945T (fr)
SI (2)	SI2336120T1 (fr)
TW (1)	TWI528961B (fr)
UA (1)	UA97658C2 (fr)
ZA (1)	ZA200903898B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN106496187A (zh) *	2016-09-14	2017-03-15	陕西科技大学	一种制备PARP抑制剂Niraparib的合成方法
CN106432187A (zh) *	2016-09-17	2017-02-22	青岛云天生物技术有限公司	2‑[4‑(‑3‑哌啶基)苯基]‑2h‑吲唑‑7‑甲酰胺的手性拆分方法
CN106432188A (zh) *	2016-09-17	2017-02-22	青岛辰达生物科技有限公司	一种抗癌药2‑[4‑((3s)‑3‑哌啶基)苯基]‑2h‑吲唑‑7‑甲酰胺的制备方法
CN106467513A (zh) *	2016-09-30	2017-03-01	陕西科技大学	一种制备Niraparib的合成方法
CN106632244A (zh) *	2016-09-30	2017-05-10	陕西科技大学	一种制备抗癌药物Niraparib的新型合成方法
CN108201537A (zh) *	2016-12-16	2018-06-26	苏州苏融生物医药有限公司	一种尼拉帕尼缓控释药物组合物及其用途
BR112019020191A2 (pt) *	2017-03-27	2020-04-22	Tesaro Inc	formulações de niraparib
CN109081828B (zh) *	2017-06-14	2021-03-26	上海时莱生物技术有限公司	聚(adp-核糖)聚合酶抑制剂、制备方法及用途
CA3076907A1 (fr)	2017-09-26	2019-04-04	Tesaro, Inc.	Formulations de niraparib
CN108084157A (zh) *	2018-02-12	2018-05-29	安庆奇创药业有限公司	一种尼拉帕尼的合成方法
CN108203404A (zh) *	2018-03-02	2018-06-26	上海博邦医药科技有限公司	(r)-3-苯基哌啶或/和(s)-3-苯基哌啶以及尼拉帕尼的手性中间体的合成方法
EP4112049A4 (fr)	2020-02-24	2024-07-24	Fukang (Shanghai) Health Technology Co., Ltd.	Application anti-coronavirus de l'inhibiteur de la poly adp-ribose polymérase
CN115611860B (zh) *	2021-07-13	2024-06-11	上海博璞诺科技发展有限公司	合成尼拉帕尼的方法

2007
- 2007-01-10 GB GBGB0700432.8A patent/GB0700432D0/en not_active Ceased
2008
- 2008-01-08 UA UAA200908335A patent/UA97658C2/ru unknown
- 2008-01-08 PT PT14176452T patent/PT2805945T/pt unknown
- 2008-01-08 DE DE602008005711T patent/DE602008005711D1/de active Active
- 2008-01-08 LT LTEP14176452.2T patent/LT2805945T/lt unknown
- 2008-01-08 PE PE2008000097A patent/PE20081558A1/es active IP Right Grant
- 2008-01-08 SI SI200831266T patent/SI2336120T1/sl unknown
- 2008-01-08 TW TW097100730A patent/TWI528961B/zh active
- 2008-01-08 PT PT08702101T patent/PT2109608E/pt unknown
- 2008-01-08 NZ NZ578256A patent/NZ578256A/en unknown
- 2008-01-08 PT PT111573697T patent/PT2336120E/pt unknown
- 2008-01-08 SI SI200830240T patent/SI2109608T1/sl unknown
- 2008-01-08 HU HUE14176452 patent/HUE044513T2/hu unknown
- 2008-01-08 MY MYPI20092876A patent/MY147789A/en unknown
- 2008-01-08 ES ES08702101T patent/ES2362214T3/es active Active
- 2008-01-08 ES ES11157369.7T patent/ES2509115T3/es active Active
- 2008-01-08 DK DK11157369.7T patent/DK2336120T3/da active
- 2008-01-08 DK DK08702101.0T patent/DK2109608T3/da active
- 2008-01-08 ES ES14176452T patent/ES2728199T3/es active Active
- 2008-01-08 CN CN2008800019265A patent/CN101578279B/zh active Active
- 2008-01-08 AT AT08702101T patent/ATE502933T1/de active
- 2008-01-08 ME MEP-2019-147A patent/ME03481B/fr unknown
2009
- 2009-06-04 ZA ZA200903898A patent/ZA200903898B/xx unknown
- 2009-07-02 CR CR10910A patent/CR10910A/es unknown
- 2009-07-02 NI NI200900135A patent/NI200900135A/es unknown
- 2009-07-02 HN HN2009001260A patent/HN2009001260A/es unknown
2018
- 2018-05-03 LU LU00072C patent/LUC00072I2/fr unknown

Also Published As

Publication number	Publication date
TW200836731A (en)	2008-09-16
PT2805945T (pt)	2019-06-06
SI2336120T1 (sl)	2014-10-30
GB0700432D0 (en)	2007-02-21
DK2109608T3 (da)	2011-07-11
SI2109608T1 (sl)	2011-07-29
LT2805945T (lt)	2019-06-25
ATE502933T1 (de)	2011-04-15
NZ578256A (en)	2011-12-22
ME03481B (fr)	2020-01-20
UA97658C2 (ru)	2012-03-12
MY147789A (en)	2013-01-31
ES2362214T3 (es)	2011-06-29
NI200900135A (es)	2010-08-30
CN101578279A (zh)	2009-11-11
PT2109608E (pt)	2011-05-30
CR10910A (es)	2010-01-19
ZA200903898B (en)	2010-04-28
PT2336120E (pt)	2014-10-01
DK2336120T3 (da)	2014-10-06
HUE044513T2 (hu)	2019-10-28
DE602008005711D1 (de)	2011-05-05
CN101578279B (zh)	2013-07-17
PE20081558A1 (es)	2008-10-30
ES2509115T3 (es)	2014-10-17
TWI528961B (zh)	2016-04-11
HN2009001260A (es)	2012-03-26
ES2728199T3 (es)	2019-10-22

Publication	Publication Date	Title
LUC00072I2 (fr)	2018-07-04	Niraparib ou un sel pharmaceutiquement acceptable, stéréoisomère ou tautomère de celui-ci, notamment le tosylate ou un hydrate, particulièrement le tosylate monohydraté
MX2009007200A (es)	2009-07-15	Indazoles sustituidos con amida como inhibidores de poli(adp-ribosa)polimerasa (parp).
MX2010005070A (es)	2010-05-24	Derivados de piridazinona como inhibidores de parp.
WO2007138351A3 (fr)	2008-08-07	Dérivés de pyridinone et de pyridazinone inhibiteurs de la poly(adp-ribose)polymérase (parp)
MX2012002179A (es)	2012-03-16	Compuestos heterociclicos de oxima.
MA37866B1 (fr)	2016-12-30	Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
MX346186B (es)	2017-03-10	Inhibidores de proteina cinasas.
WO2010054278A3 (fr)	2010-12-23	Composés pour traiter les troubles inflammatoires
EA201100580A1 (ru)	2011-10-31	Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
TW201000488A (en)	2010-01-01	Heterocyclic derivatives
MX2012001838A (es)	2012-02-29	Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
WO2012117000A8 (fr)	2013-03-07	3-aminopyridines en tant qu'agonistes de gpbar1
MX2012007582A (es)	2012-07-30	Compuestos de 4-fenoxi-nicotinamida o 4-fenoxi-pirimidina-5-carbox amida.
WO2008017883A3 (fr)	2008-04-03	Dérivés de 4-oxo-4,5-dihydropyrrolo[1,2-a]quinoxaline en tant qu'inhibiteurs de poly(adp-ribose)polymérase(parp)
WO2011147951A8 (fr)	2012-03-15	Dérivés de cycloamino comme antagonistes du gpr119
PH12015500418A1 (en)	2015-04-20	Pyridine derivative and medicine
MY148254A (en)	2013-03-29	Tartrate derivatives for use as coagulation factor ixa inhibitors
MX2009009409A (es)	2009-09-14	Compuestos que tienen estructura aril-sulfonamidica utiles como inhibidores de metaloproteasas.